"The mechanism behind the Kaposi’s sarcoma-associated herpesvirus (KSHV) that causes healthy cells to become malignant is not well understood despite two decades of intensive studies," said S. …
This mutation, called "V60L," is at present the most common among people from Mediterranean regions such as Spain, Portugal, Italy and Israel. It is present in about 10-20% of the population, according to the study carried out by researchers at the Universitat Jaume I and the University of the Basque Country performed on over 1,000 individuals from different areas of Spain. …
Burkitt lymphoma is the most aggressive type of lymphoma, which is a cancer that begins in cells of the immune system. It is more common in equatorial Africa than in Western countries. In Uganda, for example, the estimated prevalence of Burkitt lymphoma is between 5 and 20 cases per 100,000 inhabitants, whereas in the United States, according to NCI’s statistical database for 2001-2009, prevalence was 0.4 cases per 100,000 inhabitants…
"This is the first mutation found that can explain the gender disparity in incidence of hepatocellular carcinoma," says Bum-Joon Kim of Seoul National University, Korea, an author on the study. In the study, the researchers randomly collected and analyzed serum samples from 292 patients with chronic HBV infection who visited one of 3 hospitals in Korea from 2003-2005. Previous studies had suggested that a gene mutation known as W4P/R was associated with higher incidence of liver cancer and cirrhosis. They developed an assay to specifically identify HBV with the W4P/R mutation…
Very young patients To make up for the lack of knowledge on liver cancer in Latin America, the researchers performed a statistical analysis of clinical cases of the disease in Peru, the country reputed to have the highest incidence on the continent. They sifted through the demographic characteristics, risk factors and causes for more than 1,500 patients from throughout the country, admitted between 1997 and 2010 at the Instituto Nacional de Enfermedades Neoplásicas (Inen ) in Lima. Their results were unexpected: 50% of the people affected do not at all match the profile of those at risk. They are young people with an average age of 25, some even children, who for the most part do not have the hepatitis B or C virus nor do they suffer from cirrhosis. …
The researchers altered the amino acid sequence of a cystine knot peptide — or knottin — derived from the seeds of the squirting cucumber, a plant native to Europe, North Africa and parts of Asia. Peptides are short chains of amino acids that are integral to cellular processes; knottin peptides are notable for their stability and resistance to breakdown. The team used their invention as a "molecular flashlight" to distinguish tumors from surrounding healthy tissue. After injecting their bioengineered knottin into the bloodstreams of mice with medulloblastomas, the researchers found that the peptide stuck tightly to the tumors and could be detected using a high-sensitivity digital camera. …
In addition to causing cervical, anal and genital cancers, HPV has more recently been found to cause some head and neck cancers. "One of the main issues is this form of esophageal cancer is usually diagnosed quite late and so has a very high mortality," says the first author of the paper, Dr Surabhi Liyanage, a PhD candidate with the School of Public Health and Community Medicine, UNSW Medicine…
source : http://www.foxnews.com/health/2013/06/26/lure-variety-designer-drugs-is-alarming-un-agency-says/
source : http://www.foxnews.com/health/2013/06/25/7-african-countries-cut-child-hiv-infections-by-half/
A daily dose of powerful anti-HIV medicine helped cut the risk of infection with the AIDS virus by 49 percent in intravenous drug users in a Bangkok study that showed for the first time such a preventive step can work in this high-risk population. “This is a significant step forward for HIV prevention,” said Dr. Jonathan Mermin, director of the U.S. Centers for Disease Control and Prevention, which helped conduct the clinical trial along with the Thailand Ministry of Health. The study, published on Wednesday in the journal Lancet, looked at the treatment approach known as pre-exposure prophylaxis, or PrEP, in which HIV treatments are given to uninfected people who are at high-risk for HIV infection. The drug used in the study was Gilead's older and relatively cheap generic HIV drug tenofovir. The study was launched in 2005. Prior studies of this approach showed it cut infection rates by 44 percent in men who have sex with men, by 62 percent in heterosexual men and women and by 75 percent in couples in which one partner is infected with HIV and the other is not. The new results showed that it also protects intravenous drug users. “We now know that PrEP can work for all populations at increased risk for HIV,” Mermin said in a statement. Based on the results, the CDC plans to recommend that U.S. doctors who wish to prescribe this treatment for their patients follow the same interim guidelines issued last year to prevent sexual transmission among other high-risk individuals. Intravenous use of drugs like heroin accounts for about 8 percent of all new HIV infections in the United States and about 10 percent of new HIV infections worldwide. In some regions, such as Eastern Europe and Central Asia, injection drug abuse accounts for about 80 percent of all new infections. The new findings involved more than 2,400 intravenous drug users in Bangkok who were not infected with the human immunodeficiency virus, which causes AIDS, and were being treated at the city's drug treatment clinics. Half took tenofovir and half took a placebo. All participants were given HIV prevention counseling, risk-reduction strategies such as condoms and methadone treatment, and monthly HIV testing. At the end of the study, there were 17 HIV infections among people taking the HIV medication, compared with 33 infections among those not taking the drugs, the researchers found. The researchers also looked to see what factors influenced infection rates among those taking the HIV medication. They found that people who took their medication at least 71 percent of the time had a 74 percent lower risk of becoming infected with HIV. Although it was not clear how the preventive drug treatment worked - by stopping infections caused by sharing dirty needles or by unprotected sex among drug users - the study produced a reduction in infection rates, said Dr. Salim Abdook Karim of the University of KwaZulu-Natal in Durban, South Africa and of Columbia University in New York. “The introduction of PrEP for HIV prevention in injecting drug users should be considered as an additional component to accompany other proven prevention strategies like needle exchange programs, methadone programs, promotion of safer sex and injecting practices, condoms, and HIV counseling and testing,” Karim, who was not involved in the study, wrote in a commentary accompanying the study in the Lancet. “PrEP as part of combination prevention in injecting drug users could make a useful contribution to the quest for an AIDS-free generation,” Karim added.source : http://www.foxnews.com/health/2013/06/13/aids-drugs-halve-hiv-risk-for-intravenous-drug-users-in-study/